company background image
0R72 logo

Biocartis Group LSE:0R72 Stock Report

Last Price

€0.30

Market Cap

€27.2m

7D

0%

1Y

-43.9%

Updated

23 Dec, 2023

Data

Company Financials +

0R72 Stock Overview

Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology.

0R72 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Biocartis Group NV Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Biocartis Group
Historical stock prices
Current Share Price€0.30
52 Week High€0.76
52 Week Low€0.30
Beta1.38
1 Month Change0%
3 Month Change4.00%
1 Year Change-43.90%
3 Year Change-93.57%
5 Year Change-97.01%
Change since IPO-97.88%

Recent News & Updates

Recent updates

Shareholder Returns

0R72GB Medical EquipmentGB Market
7D0%-3.4%-0.5%
1Y-43.9%-1.5%0.6%

Return vs Industry: 0R72 underperformed the UK Medical Equipment industry which returned -3.9% over the past year.

Return vs Market: 0R72 underperformed the UK Market which returned -0.6% over the past year.

Price Volatility

Is 0R72's price volatile compared to industry and market?
0R72 volatility
0R72 Average Weekly Movementn/a
Medical Equipment Industry Average Movement7.6%
Market Average Movement4.7%
10% most volatile stocks in GB Market11.3%
10% least volatile stocks in GB Market2.5%

Stable Share Price: 0R72 has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine 0R72's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2007526Roger Moodyhttps://www.biocartisgroupnv.be

Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progress monitoring. The company offers Idylla BRAF, KRAS, MSI, EGFR, and NRAS-BRAF mutation tests; and Idylla SARS-CoV-2/Flu/RSV panels and SARS-CoV-2 tests, as well as SeptiCyte RAPID, a rapid host-response test.

Biocartis Group NV Fundamentals Summary

How do Biocartis Group's earnings and revenue compare to its market cap?
0R72 fundamental statistics
Market cap€27.24m
Earnings (TTM)-€67.87m
Revenue (TTM)€60.82m

0.4x

P/S Ratio

-0.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0R72 income statement (TTM)
Revenue€60.82m
Cost of Revenue€65.51m
Gross Profit-€4.69m
Other Expenses€63.18m
Earnings-€67.87m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.72
Gross Margin-7.71%
Net Profit Margin-111.58%
Debt/Equity Ratio-257.9%

How did 0R72 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.